New Delhi, September 21, 2025 – India is making significant strides in the global natural healthcare sector by blending ancient Ayurvedic wisdom with cutting-edge scientific validation, aiming to deliver affordable and effective herbal remedies worldwide. This momentum was evident at the two-day CSIR Startup Conclave, where government-backed research institutions unveiled 13 innovative herbal drugs targeting chronic and lifestyle ailments like diabetes, blood cancer, fatty liver, and liver degeneration. The event underscored a seamless "lab to market" transition, fostering collaborations among scientists, startups, and policymakers to tap into the booming international demand for natural therapies.TRASE Block Heels Sandals For Women, Dusky Stylish & Comfortable Footwear

Union Science and Technology Minister Dr. Jitendra Singh, who inaugurated the conclave, emphasized the potential of these innovations. "This is a shining example of the 'lab to people' model of innovation," he stated, urging startups to scale these government-developed technologies for global export. Uttar Pradesh Chief Minister Yogi Adityanath echoed this sentiment during his visit to the exhibition, calling on researchers to fast-track the commercialization of herbal solutions to address pressing health challenges.

Breakthrough Herbal Drugs from CSIR- LabsThe Council of Scientific and Industrial Research (CSIR), India's premier R&D organization, has spearheaded the development through its specialized labs. Key institutions include the National Botanical Research Institute (NBRI) in Lucknow, Central Institute of Medicinal and Aromatic Plants (CIMAP), Indian Institute of Toxicology Research (IITR), and Central Drug Research Institute (CDRI). These efforts focus on evidence-based formulations derived from indigenous plants, ensuring safety, efficacy, and scalability.Also Read: Today is Mahalaya Amavasya: Auspicious Day of Pitru Paksha – Background of the Name "Mahalaya" & Observance

Drug/Product-

BGR-34- Target Condition(Diabetes)-

Key Ingredients/Notes- Daruharidra, Giloy, Vijaysar, Gudmar, Manjistha, Methi; Regulates blood sugar; Potential for long-term reversal

-Developers- NBRI & CIMAP (jointly); Marketed by AIMIL Pharmaceuticals

Paclitaxel- Blood Cancer-Derived from Arjuna tree bark; Chemotherapy agent-CDRI

-Picroliv-Fatty Liver & Liver Degeneration-Herbal extract for liver protection-CIMAP

BGR-34 stands out as a flagship product, already commercially available through AIMIL Pharmaceuticals. Dr. Sanchit Sharma, Executive Director of AIMIL, highlighted its transformative potential: "Worldwide, the narrative is moving beyond diabetes control to diabetes reversal. Formulations like BGR-34 represent the synergy of Ayurveda and modern science, and such models could become the foundation for a diabetes-free society in the years to come."